Does the media prefer NTLA or KYTX?

In the previous week, Kyverna Therapeutics had 2 more articles in the media than Intellia Therapeutics. MarketBeat recorded 4 mentions for Kyverna Therapeutics and 2 mentions for Intellia Therapeutics. Intellia Therapeutics' average media sentiment score of 0.64 beat Kyverna Therapeutics' score of 0.25 indicating that Intellia Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Intellia Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kyverna Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media prefer KYTX or STOK?

In the previous week, Stoke Therapeutics had 5 more articles in the media than Kyverna Therapeutics. MarketBeat recorded 9 mentions for Stoke Therapeutics and 4 mentions for Kyverna Therapeutics. Stoke Therapeutics' average media sentiment score of 0.73 beat Kyverna Therapeutics' score of 0.25 indicating that Stoke Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kyverna Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Stoke Therapeutics 4 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is TSHA or KYTX more profitable?

Taysha Gene Therapies' return on equity of -56.19% beat Kyverna Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Taysha Gene Therapies N/A -56.19% -41.84% Kyverna Therapeutics N/A -81.92% -63.74%

Does the media favor TSHA or KYTX?

In the previous week, Kyverna Therapeutics had 1 more articles in the media than Taysha Gene Therapies. MarketBeat recorded 4 mentions for Kyverna Therapeutics and 3 mentions for Taysha Gene Therapies. Taysha Gene Therapies' average media sentiment score of 0.37 beat Kyverna Therapeutics' score of 0.25 indicating that Taysha Gene Therapies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Taysha Gene Therapies 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Kyverna Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media prefer SNDX or KYTX?

In the previous week, Syndax Pharmaceuticals had 9 more articles in the media than Kyverna Therapeutics. MarketBeat recorded 13 mentions for Syndax Pharmaceuticals and 4 mentions for Kyverna Therapeutics. Syndax Pharmaceuticals' average media sentiment score of 0.48 beat Kyverna Therapeutics' score of 0.25 indicating that Syndax Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Syndax Pharmaceuticals 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Kyverna Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has better valuation & earnings, KYTX or NBTX?

Nanobiotix has higher revenue and earnings than Kyverna Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kyverna Therapeutics N/A N/A -$161.31M -$2.94 N/A Nanobiotix $36.87M 35.35 -$27.11M N/A N/A

Is KYTX or NBTX more profitable?

Nanobiotix's return on equity of 0.00% beat Kyverna Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Kyverna Therapeutics N/A -81.92% -63.74% Nanobiotix N/A N/A N/A

Does the media prefer KYTX or NBTX?

In the previous week, Nanobiotix had 5 more articles in the media than Kyverna Therapeutics. MarketBeat recorded 9 mentions for Nanobiotix and 4 mentions for Kyverna Therapeutics. Kyverna Therapeutics' average media sentiment score of 0.25 beat Nanobiotix's score of -0.16 indicating that Kyverna Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kyverna Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Nanobiotix 0 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Kyverna Therapeutics (KYTX) Competitors

$6.22 -0.30 (-4.60%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$6.41 +0.19 (+3.05%)

As of 10/2/2026 07:57 PM Eastern

Compare

KYTX vs. NTLA, STOK, TSHA, SNDX, and NBTX

Should you buy Kyverna Therapeutics stock or one of its competitors? Kyverna Therapeutics's main competitors and comparable companies include Intellia Therapeutics (NTLA), Stoke Therapeutics (STOK), Taysha Gene Therapies (TSHA), Syndax Pharmaceuticals (SNDX), and Nanobiotix (NBTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Kyverna Therapeutics compare to Intellia Therapeutics?

Intellia Therapeutics (NASDAQ:NTLA) and Kyverna Therapeutics (NASDAQ:KYTX) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, valuation, risk, analyst recommendations, institutional ownership, earnings, profitability and media sentiment.

In the previous week, Kyverna Therapeutics had 2 more articles in the media than Intellia Therapeutics. MarketBeat recorded 4 mentions for Kyverna Therapeutics and 2 mentions for Intellia Therapeutics. Intellia Therapeutics' average media sentiment score of 0.64 beat Kyverna Therapeutics' score of 0.25 indicating that Intellia Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Intellia Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kyverna Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

88.8% of Intellia Therapeutics shares are held by institutional investors. Comparatively, 18.1% of Kyverna Therapeutics shares are held by institutional investors. 3.5% of Intellia Therapeutics shares are held by insiders. Comparatively, 17.6% of Kyverna Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Kyverna Therapeutics has lower revenue, but higher earnings than Intellia Therapeutics. Intellia Therapeutics is trading at a lower price-to-earnings ratio than Kyverna Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intellia Therapeutics	$67.67M	25.39	-$412.69M	-$3.36	N/A
Kyverna Therapeutics	N/A	N/A	-$161.31M	-$2.94	N/A

Intellia Therapeutics has a beta of 1.8, indicating that its stock price is 80% more volatile than the broader market. Comparatively, Kyverna Therapeutics has a beta of 2.06, indicating that its stock price is 106% more volatile than the broader market.

Intellia Therapeutics currently has a consensus price target of $20.98, suggesting a potential upside of 71.11%. Kyverna Therapeutics has a consensus price target of $29.00, suggesting a potential upside of 366.24%. Given Kyverna Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Kyverna Therapeutics is more favorable than Intellia Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intellia Therapeutics	4 Sell rating(s)	8 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.35
Kyverna Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

Kyverna Therapeutics has a net margin of 0.00% compared to Intellia Therapeutics' net margin of -672.16%. Intellia Therapeutics' return on equity of -57.79% beat Kyverna Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Intellia Therapeutics	-672.16%	-57.79%	-47.29%
Kyverna Therapeutics	N/A	-81.92%	-63.74%

Summary

Kyverna Therapeutics beats Intellia Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Kyverna Therapeutics compare to Stoke Therapeutics?

Kyverna Therapeutics (NASDAQ:KYTX) and Stoke Therapeutics (NASDAQ:STOK) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, valuation, analyst recommendations, risk, media sentiment, earnings, dividends and institutional ownership.

Kyverna Therapeutics has a beta of 2.06, suggesting that its share price is 106% more volatile than the broader market. Comparatively, Stoke Therapeutics has a beta of 1.26, suggesting that its share price is 26% more volatile than the broader market.

18.1% of Kyverna Therapeutics shares are held by institutional investors. 17.6% of Kyverna Therapeutics shares are held by company insiders. Comparatively, 9.6% of Stoke Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Kyverna Therapeutics presently has a consensus target price of $29.00, suggesting a potential upside of 366.24%. Stoke Therapeutics has a consensus target price of $44.25, suggesting a potential upside of 72.72%. Given Kyverna Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Kyverna Therapeutics is more favorable than Stoke Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kyverna Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Stoke Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82

In the previous week, Stoke Therapeutics had 5 more articles in the media than Kyverna Therapeutics. MarketBeat recorded 9 mentions for Stoke Therapeutics and 4 mentions for Kyverna Therapeutics. Stoke Therapeutics' average media sentiment score of 0.73 beat Kyverna Therapeutics' score of 0.25 indicating that Stoke Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kyverna Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Stoke Therapeutics	4 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Stoke Therapeutics has higher revenue and earnings than Kyverna Therapeutics. Stoke Therapeutics is trading at a lower price-to-earnings ratio than Kyverna Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kyverna Therapeutics	N/A	N/A	-$161.31M	-$2.94	N/A
Stoke Therapeutics	$184.42M	8.96	-$6.89M	-$3.34	N/A

Kyverna Therapeutics has a net margin of 0.00% compared to Stoke Therapeutics' net margin of -753.60%. Stoke Therapeutics' return on equity of -59.36% beat Kyverna Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kyverna Therapeutics	N/A	-81.92%	-63.74%
Stoke Therapeutics	-753.60%	-59.36%	-51.46%

Summary

Kyverna Therapeutics beats Stoke Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Kyverna Therapeutics compare to Taysha Gene Therapies?

Taysha Gene Therapies (NASDAQ:TSHA) and Kyverna Therapeutics (NASDAQ:KYTX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, risk, earnings, profitability, media sentiment, valuation and analyst recommendations.

Taysha Gene Therapies currently has a consensus price target of $12.77, indicating a potential upside of 175.79%. Kyverna Therapeutics has a consensus price target of $29.00, indicating a potential upside of 366.24%. Given Kyverna Therapeutics' higher possible upside, analysts clearly believe Kyverna Therapeutics is more favorable than Taysha Gene Therapies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Taysha Gene Therapies	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	3.00
Kyverna Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

Taysha Gene Therapies' return on equity of -56.19% beat Kyverna Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Taysha Gene Therapies	N/A	-56.19%	-41.84%
Kyverna Therapeutics	N/A	-81.92%	-63.74%

77.7% of Taysha Gene Therapies shares are owned by institutional investors. Comparatively, 18.1% of Kyverna Therapeutics shares are owned by institutional investors. 3.5% of Taysha Gene Therapies shares are owned by insiders. Comparatively, 17.6% of Kyverna Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Taysha Gene Therapies has higher revenue and earnings than Kyverna Therapeutics. Taysha Gene Therapies is trading at a lower price-to-earnings ratio than Kyverna Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Taysha Gene Therapies	$9.77M	154.41	-$109M	-$0.42	N/A
Kyverna Therapeutics	N/A	N/A	-$161.31M	-$2.94	N/A

In the previous week, Kyverna Therapeutics had 1 more articles in the media than Taysha Gene Therapies. MarketBeat recorded 4 mentions for Kyverna Therapeutics and 3 mentions for Taysha Gene Therapies. Taysha Gene Therapies' average media sentiment score of 0.37 beat Kyverna Therapeutics' score of 0.25 indicating that Taysha Gene Therapies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Taysha Gene Therapies	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kyverna Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Taysha Gene Therapies has a beta of 1.19, meaning that its stock price is 19% more volatile than the broader market. Comparatively, Kyverna Therapeutics has a beta of 2.06, meaning that its stock price is 106% more volatile than the broader market.

Summary

Taysha Gene Therapies beats Kyverna Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Kyverna Therapeutics compare to Syndax Pharmaceuticals?

Syndax Pharmaceuticals (NASDAQ:SNDX) and Kyverna Therapeutics (NASDAQ:KYTX) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, valuation, risk, dividends, analyst recommendations, institutional ownership and media sentiment.

Kyverna Therapeutics has a net margin of 0.00% compared to Syndax Pharmaceuticals' net margin of -87.52%. Kyverna Therapeutics' return on equity of -81.92% beat Syndax Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Syndax Pharmaceuticals	-87.52%	-372.94%	-39.11%
Kyverna Therapeutics	N/A	-81.92%	-63.74%

Syndax Pharmaceuticals has a beta of 0.42, meaning that its share price is 58% less volatile than the broader market. Comparatively, Kyverna Therapeutics has a beta of 2.06, meaning that its share price is 106% more volatile than the broader market.

Kyverna Therapeutics has lower revenue, but higher earnings than Syndax Pharmaceuticals. Syndax Pharmaceuticals is trading at a lower price-to-earnings ratio than Kyverna Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Syndax Pharmaceuticals	$172.35M	9.05	-$285.42M	-$2.51	N/A
Kyverna Therapeutics	N/A	N/A	-$161.31M	-$2.94	N/A

In the previous week, Syndax Pharmaceuticals had 9 more articles in the media than Kyverna Therapeutics. MarketBeat recorded 13 mentions for Syndax Pharmaceuticals and 4 mentions for Kyverna Therapeutics. Syndax Pharmaceuticals' average media sentiment score of 0.48 beat Kyverna Therapeutics' score of 0.25 indicating that Syndax Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Syndax Pharmaceuticals	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kyverna Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

18.1% of Kyverna Therapeutics shares are held by institutional investors. 4.8% of Syndax Pharmaceuticals shares are held by company insiders. Comparatively, 17.6% of Kyverna Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Syndax Pharmaceuticals presently has a consensus target price of $41.80, suggesting a potential upside of 137.50%. Kyverna Therapeutics has a consensus target price of $29.00, suggesting a potential upside of 366.24%. Given Kyverna Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Kyverna Therapeutics is more favorable than Syndax Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Syndax Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82
Kyverna Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

Summary

Kyverna Therapeutics beats Syndax Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does Kyverna Therapeutics compare to Nanobiotix?

Kyverna Therapeutics (NASDAQ:KYTX) and Nanobiotix (NASDAQ:NBTX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, dividends, earnings, profitability, media sentiment and institutional ownership.

Nanobiotix has higher revenue and earnings than Kyverna Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kyverna Therapeutics	N/A	N/A	-$161.31M	-$2.94	N/A
Nanobiotix	$36.87M	35.35	-$27.11M	N/A	N/A

18.1% of Kyverna Therapeutics shares are held by institutional investors. Comparatively, 38.8% of Nanobiotix shares are held by institutional investors. 17.6% of Kyverna Therapeutics shares are held by company insiders. Comparatively, 3.5% of Nanobiotix shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Kyverna Therapeutics currently has a consensus target price of $29.00, indicating a potential upside of 366.24%. Nanobiotix has a consensus target price of $46.67, indicating a potential upside of 81.23%. Given Kyverna Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Kyverna Therapeutics is more favorable than Nanobiotix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kyverna Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Nanobiotix	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Nanobiotix had 5 more articles in the media than Kyverna Therapeutics. MarketBeat recorded 9 mentions for Nanobiotix and 4 mentions for Kyverna Therapeutics. Kyverna Therapeutics' average media sentiment score of 0.25 beat Nanobiotix's score of -0.16 indicating that Kyverna Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kyverna Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Nanobiotix	0 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Nanobiotix's return on equity of 0.00% beat Kyverna Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kyverna Therapeutics	N/A	-81.92%	-63.74%
Nanobiotix	N/A	N/A	N/A

Kyverna Therapeutics has a beta of 2.06, indicating that its share price is 106% more volatile than the broader market. Comparatively, Nanobiotix has a beta of 0.79, indicating that its share price is 21% less volatile than the broader market.

Summary

Kyverna Therapeutics beats Nanobiotix on 7 of the 13 factors compared between the two stocks.

Get Kyverna Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KYTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KYTX vs. The Competition

Export

Metric	Kyverna Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$384.66M	$3.86B	$7.15B	$13.28B
Dividend Yield	N/A	3.65%	2.54%	17.33%
P/E Ratio	-2.12	13.06	275.67	26.04
Price / Sales	N/A	1,292.17	656.66	110.58
Price / Cash	N/A	123.39	78.87	52.62
Price / Book	1.62	16.63	10.93	6.31
Net Income	-$161.31M	-$22.71M	$3.51B	$362.16M
7 Day Performance	-8.66%	-2.99%	-2.00%	-1.66%
1 Month Performance	-24.61%	-10.81%	-6.19%	-4.68%
1 Year Performance	12.68%	19.19%	8.03%	1.57%

Kyverna Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KYTX Kyverna Therapeutics	2.049 of 5 stars	$6.22 -4.6%	$29.00 +366.2%	+12.7%	$384.66M	N/A	N/A	149	News Coverage
NTLA Intellia Therapeutics	2.6087 of 5 stars	$12.03 +5.3%	$20.98 +74.4%	-38.6%	$1.69B	$67.67M	N/A	377
STOK Stoke Therapeutics	3.2466 of 5 stars	$25.88 +1.5%	$44.25 +71.0%	+0.2%	$1.67B	$184.42M	N/A	170	News Coverage
TSHA Taysha Gene Therapies	2.326 of 5 stars	$4.99 flat	$12.77 +155.9%	-2.7%	$1.63B	$9.77M	N/A	99	News Coverage Positive News Gap Up
SNDX Syndax Pharmaceuticals	2.7372 of 5 stars	$18.24 +2.1%	$41.80 +129.2%	+12.8%	$1.62B	$172.35M	N/A	298	Trending News Analyst Forecast Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KYTX) was last updated on 10/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Kyverna Therapeutics (KYTX) Competitors

KYTX vs. NTLA, STOK, TSHA, SNDX, and NBTX

How does Kyverna Therapeutics compare to Intellia Therapeutics?

Summary

How does Kyverna Therapeutics compare to Stoke Therapeutics?

Summary

How does Kyverna Therapeutics compare to Taysha Gene Therapies?

Summary

How does Kyverna Therapeutics compare to Syndax Pharmaceuticals?

Summary

How does Kyverna Therapeutics compare to Nanobiotix?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KYTX vs. The Competition

Kyverna Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Kyverna Therapeutics (KYTX) Competitors

KYTX vs. NTLA, STOK, TSHA, SNDX, and NBTX

How does Kyverna Therapeutics compare to Intellia Therapeutics?

Does the media prefer NTLA or KYTX?

Do institutionals and insiders believe in NTLA or KYTX?

Which has higher earnings and valuation, NTLA or KYTX?

Which has more volatility & risk, NTLA or KYTX?

Do analysts prefer NTLA or KYTX?

Is NTLA or KYTX more profitable?

Summary

How does Kyverna Therapeutics compare to Stoke Therapeutics?

Which has more risk & volatility, KYTX or STOK?

Do institutionals & insiders have more ownership in KYTX or STOK?

Do analysts prefer KYTX or STOK?

Does the media prefer KYTX or STOK?

Which has higher earnings and valuation, KYTX or STOK?

Is KYTX or STOK more profitable?

Summary

How does Kyverna Therapeutics compare to Taysha Gene Therapies?

Do analysts rate TSHA or KYTX?

Is TSHA or KYTX more profitable?

Do institutionals & insiders have more ownership in TSHA or KYTX?

Which has better valuation & earnings, TSHA or KYTX?

Does the media favor TSHA or KYTX?

Which has more volatility and risk, TSHA or KYTX?

Summary

How does Kyverna Therapeutics compare to Syndax Pharmaceuticals?

Is SNDX or KYTX more profitable?

Which has more volatility and risk, SNDX or KYTX?

Which has higher earnings & valuation, SNDX or KYTX?

Does the media prefer SNDX or KYTX?

Do institutionals and insiders hold more shares of SNDX or KYTX?

Do analysts prefer SNDX or KYTX?

Summary

How does Kyverna Therapeutics compare to Nanobiotix?

Which has better valuation & earnings, KYTX or NBTX?

Do insiders and institutionals have more ownership in KYTX or NBTX?

Do analysts recommend KYTX or NBTX?

Does the media prefer KYTX or NBTX?

Is KYTX or NBTX more profitable?

Which has more risk & volatility, KYTX or NBTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KYTX vs. The Competition

Kyverna Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools